Exyte’s Acquisition of Critical Process Systems Group
August 24, 2021
On August 24, 2021, Exyte Group (“Exyte”) and Wynnchurch Capital announced that they had reached an agreement for an all-share acquisition of Critical Process Systems Group, a group of manufacturing and design companies, by Exyte, a global leader in the design, engineering, and delivery of high-tech facilities. Cravath is representing Exyte in connection with the transaction.
The Cravath team includes associate Richard E. Schwartz on M&A matters; partner J. Leonard Teti II and associates Cecily Xi and Rebecca L. Fine on tax matters; partner Margaret T. Segall and practice area attorney Nicole M. Peles on regulatory matters; partner John D. Buretta and practice area attorneys Megan Y. Lew and Alexander S. del Nido on compliance matters; partner Jonathan J. Katz and associates Christopher C. Gonnella and Brendon J. Rivard on executive compensation and benefits matters; partner David J. Kappos and associate Pedraam Mirzanian on intellectual property matters; partner Matthew Morreale on environmental matters; and senior attorney Joyce Law and practice area attorney Laurel R. Berkowitz on real estate matters. Nicholas P. Principato also worked on M&A matters and Malikah I. Williams also worked on antitrust matters.
Related Practices & Industries
People
- Photo
-
-
J.D., 2005, University of Virginia School of LawOrder of the Coif
-
A.B., 1999, Princeton Universitywith Honors
- New York
Education
Admitted In
- Photo
-
-
J.D., 2008, Harvard Law Schoolcum laude
-
A.B., 2003, Harvard Collegemagna cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 1996, Georgetown University Law Centercum laude
-
B.A., 1993, University of California, Berkeley
- New York
- District of Columbia
Education
Admitted In
- Photo
-
-
LL.M., 2013, New York University School of Law
-
J.D., 2007, Benjamin N. Cardozo School of LawOrder of the Coif, Dean's Distinguished Scholar, summa cum laude
-
B.S., 2003, Cornell University
- New York
Education
Admitted In
- Photo
-
-
J.D., 1990, University of California, Berkeley, School of Law
-
B.S., 1983, University of California, Davissumma cum laude
- New York
- California
- District of Columbia
Education
Admitted In
- Photo
-
-
J.D., 1997, Columbia Law SchoolHarlan Fiske Stone Scholar
-
M.S., 1994, University of Pennsylvania
-
B.A., 1990, University of Pennsylvania
-
B.A.S., 1990, University of Pennsylvania
- New York
Education
Admitted In
- Photo
-
-
J.D., 2010, New York University School of Lawcum laude
-
A.B., 2007, Dartmouth College
- New York
Education
Admitted In
- Photo
-
-
J.D., 2010, New York University School of Lawcum laude
-
B.S., 2004, Cornell Universitymagna cum laude
- New York
Education
Admitted In
-
J.D., 1997, Boston University School of Law
-
B.Comm., 1994, University of AlbertaDistinction
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
January 22, 2025
CardWorks’s Acquisition of Ally’s Credit Card Business
On January 22, 2025, CardWorks, Inc. (“CardWorks”), a leader in credit and payments, and Ally Financial Inc. (“Ally”), a financial services company with the nation’s largest all‑digital bank and an industry‑leading auto financing business, announced that they have entered into a definitive agreement for CardWorks, and its wholly‑owned bank subsidiary, Merrick Bank, to acquire Ally’s credit card business, including a portfolio of $2.3 billion in credit card receivables with 1.3 million active cardholders as of December 31, 2024. Cravath is representing CardWorks in connection with the transaction.
Deals & Cases
January 13, 2025
Johnson & Johnson’s $14.6 Billion Acquisition of Intra‑Cellular Therapies, Inc.
On January 13, 2025, Johnson & Johnson and Intra‑Cellular Therapies, Inc. announced that they have entered into a definitive agreement under which Johnson & Johnson will acquire all outstanding shares of Intra‑Cellular Therapies, a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, for $132 per share in cash for a total equity value of approximately $14.6 billion. Cravath is representing Johnson & Johnson in connection with the transaction.
Deals & Cases
October 04, 2024
DRI Healthcare Trust’s Acquisition of Payment Streams Based on the Cas9 Gene‑Editing Technology for CASGEVY®
On October 3, 2024, DRI Healthcare Trust, a global leader in providing financing to advance innovation in the life sciences industry, announced that one of its wholly owned subsidiaries acquired a portion of Editas Medicine, Inc.'s payment rights under a non‑exclusive license of Editas' Cas9 gene‑editing technology for CASGEVY®, the only approved gene‑edited cell therapy for sickle cell disease and transfusion‑dependent beta thalassemia, for an upfront purchase price of $57 million. The transaction entitles DRI Healthcare to specific payments based on a sublicensing agreement between Editas and Vertex Pharmaceuticals Incorporated. The payments include a share of the annual license fees that Vertex pays to Editas, which can range from $5 million to $40 million, including certain sales‑based annual license fee increases, and a portion of a $50 million contingent payment to which Editas is eligible under the Vertex sublicensing agreement. Cravath is representing DRI Healthcare in connection with the transaction.
Deals & Cases
September 05, 2024
Frontier’s $20 Billion Acquisition by Verizon
On September 5, 2024, Verizon Communications Inc. and Frontier Communications Parent, Inc. (“Frontier”), the largest pure‑play fiber provider in the U.S., announced they have entered into a definitive agreement for Verizon to acquire Frontier in an all‑cash transaction valued at $20 billion. Cravath is representing Frontier in connection with the transaction.
